International Stem Cell Corp. Featured in Exclusive QualityStocks
Video Production
SCOTTSDALE, AZ--(Marketwired - Nov 14, 2013) - QualityStocks
today announces the production of stimulating videos featuring
International Stem Cell Corp. (OTCQB: ISCO), providing insight to
the exciting capabilities of stem cell research and the company's
revolutionary advances in the field of regenerative medicine.
The HD videos can be viewed at
http://Video.QualityStocks.net
ISCO was the first to develop and perfect a new class of human
stem cells created from unfertilized human eggs. The company's stem
cells present superior immune matching capabilities and can be used
in millions of people regardless of sex or racial background, with
minimal expectation of immune rejection after transplantation.
Dr. Simon Craw, EVP of business development, in the videos
details ISCO's focus on using these "next-generation" stem cells to
treat severe unmet medical needs of the central nervous system and
beyond.
"Regenerative medicine has been called the next evolution of
medical treatments by the U.S. Department of Health and Human
Services. With its potential to heal, this new field of science is
expected to revolutionize healthcare," says Dr. Craw.
In mid-2014 ISCO plans to file with the U.S. Food and Drug
Administration an investigational new drug (IND) application for
Parkinson's disease, a significant achievement that extends far
beyond the company's development.
"Filing the IND represents a big step forward for ISCO and a
major advancement to the field of Parkinson's disease research,"
emphasizes Dr. Craw. "We have not only invested in our science but
also in our manufacturing and have all the capacity we need to
manufacture human cells and related products to support our
strategic goals."
Brett Lesser, VP of Sales for LifeLine Cell Technology, one of
ISCO's wholly-owned subsidiaries that specializes in manufacturing
human cells, explains how ISCO's cellular products are utilized by
scientists searching for treatment of a number of other
disease.
"Currently our cells are being used in experiments regarding
lung cancer, breast cancer, prostate disease, COPD, asthma,
diabetes, and a myriad of other life-threatening ailments," states
Lesser. "We've grown to a point where scientists from all over the
world have published in some of the most prestigious scientific
journals about advances in their own while using our cell culture
products."
The videos also describe ISCO's self-sustaining business model,
subsidiary business units, as well as provides insight on the
company's sweeping patent portfolio and investment
opportunity.
About International Stem Cell Corp.
International Stem Cell Corp. is focused on the therapeutic
applications of human parthenogenetic stem cells (hpSCs) and the
development and commercialization of cell-based research and
cosmetic products. ISCO's core technology, parthenogenesis, results
in the creation of pluripotent human stem cells from unfertilized
oocytes (eggs) hence avoiding ethical issues associated with the
use or destruction of viable human embryos. ISCO scientists have
created the first parthenogenetic, homozygous stem cell line that
can be a source of therapeutic cells for hundreds of millions of
individuals of differing genders, ages and racial background with
minimal immune rejection after transplantation. hpSCs offer the
potential to create the first true stem cell bank, UniStemCell™.
ISCO also produces and markets specialized cells and growth media
for therapeutic research worldwide through its subsidiary Lifeline
Cell Technology (www.lifelinecelltech.com), and stem cell-based
skin care products through its subsidiary Lifeline Skin Care
(www.lifelineskincare.com).
More information is available at
www.internationalstemcell.com
For more information on International Stem Cell, Inc. visit:
http://ISCO.qualitystocks.net
About QualityStocks
Small Cap Stock Newsletter QualityStocks is a free service that
collects data from hundreds of Small-Cap and Micro-Cap online
Investment Newsletters into one free Daily Newsletter Report.
QualityStocks also utilizes social media and networking to maintain
constant communication with its rapidly growing audience.
QualityStocks is committed to connecting subscribers with
companies that have huge potential to succeed in the short and
long-term future. It is part of our mission statement to help the
investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to
learn more about investing in these companies as well as find and
evaluate them.
The QualityStocks Blog
The QualityStocks Blog keeps investors up to date on everything
related to the Small-Cap and Micro-Cap markets. Alternative fuels
and power sources, entertainment media, telecommunications,
delivery services, healthcare, and retail are all covered on a
regular basis. By visiting our blog, investors also discover
emerging companies that they otherwise would not have heard about.
To date, more than 30,000 articles have been published via the
QualityStocks Blog.
The QualityStocks Message Boards
The message board here at QualityStocks is one of the most
highly regulated, no-nonsense forums online today; an uncommon
haven of highly relevant, SPAM-free investor interaction. Unlike
the majority of boards currently in operation, you won't find
pumping, bashing, advertising, or malicious posting of any kind
here. The QualityStocks Message Boards has over 34,000 registered
users.
The QualityStocks Daily Newsletter
With all of the stock picks and recommendations available today
in the investment world, selecting and deciding on the right stocks
can be tedious and time consuming. At QualityStocks, we collate
hundreds of investment newsletters into The ONE and ONLY "The
QualityStocks Daily", featuring a summary format in which you can
view the latest stock picks EVERYDAY.
You can SIGN UP NOW http://Signup.QualityStocks.net
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Contact: Astra Thomas QualityStocks Scottsdale, Arizona
www.QualityStocks.com 480.374.1336 editor@QualityStocks.net
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Sep 2024 to Oct 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Oct 2023 to Oct 2024